Premium
Prognostic Circulating MicroRNA Biomarkers in Early‐Stage Non‐Small Cell Lung Cancer: A Role for miR‐150
Author(s) -
Wiemer Erik A.C.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.972
Subject(s) - microrna , lung cancer , biomarker , stage (stratigraphy) , medicine , oncology , cancer , bioinformatics , biology , gene , paleontology , biochemistry
Circulating microRNA biomarkers can be indicators of early‐stage non‐small cell lung cancer (NSCLC) but may also hold prognostic value. The ability to predict prognosis of early‐stage NSCLC is important, as it may potentially impact patient outcome. Studies to define these prognostic microRNA biomarkers are urgently needed. Also, insight into the biological significance of the microRNA biomarker in the cancer cell—and within the tumor—may reveal novel and therapeutically interesting signaling networks.